Increased cardiovascular morbidity and reduced life expectancy in a large Italian cohort of patients with resistance to thyroid hormone β (RTHβ)
Authors' conclusion
These data should raise the general awareness on the cardiovascular risk and prompt a proactive cardiovascular monitoring in RTHβ, especially in men and those with fT4 levels above 30 pmol/L.
Study context
- Population
- Italian RTHβ patients carrying heterozygous pathogenic THRB variants, diagnosed 1984–2023249 with longitudinal data
- Participants
- 284 patients
- Outcome
- Cardiovascular morbidity and mortality
Main finding
As reported in the abstract
Cumulative prevalence of sinus/supraventricular tachycardia
40%
Cumulative prevalence of AF
18%
Median (IQR) age at MACE
59.4 years
50.4–66.4
Mean life years lost from early mortality
11 years
Observational data: associations, not effects.
Further findings
Factors associated with MACE and mortality
- Univariable: hypertension, dyslipidemia, high fasting glucose/diabetes associated with MACE
- Multivariable: only age at diagnosis, increased FT4 and male gender associated with MACE; age at diagnosis and higher FT4 with mortality
- Previous thyroidectomy or RAI had no statistically significant effect on MACE or all-cause mortality
Original publication
Increased cardiovascular morbidity and reduced life expectancy in a large Italian cohort of patients with resistance to thyroid hormone β (RTHβ). Eur J Endocrinol. Published 27 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →